Fulvant (Fulvestrant Injection) 250mg / 5ml

Product Description

Fulvant (Fulvestrant Injection) 250 mg/5 ml is a medication used primarily in the treatment of hormone receptor-positive breast cancer in postmenopausal women. It is particularly effective in cases of metastatic breast cancer (cancer that has spread to other parts of the body), and it is used in patients who have either not responded to or have relapsed after prior treatments with other hormone therapies, such as tamoxifen.

How it works:

Fulvestrant is a selective estrogen receptor downregulator (SERD). It works by:

• Binding to estrogen receptors on cancer cells, causing the receptor to be degraded, which effectively blocks the activity of estrogen. Estrogen is a hormone that promotes the growth of hormone receptor-positive breast cancer cells.
• By blocking estrogen from binding to the receptor, Fulvestrant helps to stop the cancer cells from growing or multiplying.

Common uses:

• Metastatic breast cancer in postmenopausal women, specifically those whose cancer is hormone receptor-positive (estrogen receptor-positive or progesterone receptor-positive) and HER2-negative.
• It is often used in combination with other treatments or as a second-line or third-line therapy after other treatments have failed.

Dosage and administration:

• Fulvestrant is typically given as an intramuscular injection (IM) into the buttocks.
• The standard dose is 250 mg (5 ml) once every 2 weeks for the first 3 doses, followed by once a month thereafter.
• The injection is given by a healthcare provider, and care should be taken to ensure proper administration techniques to minimize discomfort and complications.

Possible side effects:

• Injection site reactions: Pain, redness, swelling, or bruising at the injection site.
• Hot flashes: Common with hormone therapies like Fulvestrant.
• Fatigue: Feeling unusually tired or weak.
• Nausea and vomiting.
• Muscle or joint pain.
• Liver issues: Fulvestrant can affect liver function, so liver enzyme levels should be monitored during treatment.
• Bone pain: May occur due to the drug's action on estrogen receptors in bone cells.
• Blood clots: Although rare, there is a possibility of developing blood clots while on this medication.

Warnings and precautions:

• Pregnancy: Fulvestrant should not be used during pregnancy as it can harm the fetus. Women of childbearing potential must use effective contraception during treatment and for some time after stopping the medication.
• Liver function: Fulvestrant can affect liver function, so it is important to monitor liver enzymes regularly during treatment.
• Allergic reactions: Though rare, some people may experience allergic reactions, such as rash, difficulty breathing, or swelling of the face and throat. Seek immediate medical attention if any signs of an allergic reaction occur.
• Bone health: Since Fulvestrant can affect bone density, patients may need monitoring of bone health during long-term use.

Important considerations:

• Regular follow-up: Frequent monitoring with imaging tests (such as scans) and blood tests will be required to assess the effectiveness of the treatment and to monitor for any side effects.
• Drug interactions: Inform your healthcare provider of any other medications you're taking, especially those for other medical conditions like infections, pain management, or other cancer treatments.